Bahrain Investment Firm Partially Divests from Leading Dialysis Provider NephroPlus

Bahrain-based alternative investment firm Investcorp has announced a strategic partial exit from NephroPlus, Asia's largest dialysis service provider, as part of a $102 million funding round led by Singaporean investment firm Quadria Capital.

Investcorp will retain a significant stake in NephroPlus, demonstrating continued confidence in the company's future growth trajectory. This move marks a successful chapter for Investcorp, showcasing its ability to nurture high-potential companies in India and deliver value for its investors.

The initial investment by Investcorp in NephroPlus occurred in November 2019, when the Indian dialysis leader operated approximately 180 centers. Since then, NephroPlus has experienced significant expansion, boasting a current network of 404 centers, including over 20 facilities established in the Philippines and Uzbekistan.

The funding round led by Quadria Capital will provide NephroPlus with a combination of fresh capital infusion and secondary stake purchases from existing investors. These investors include Investcorp, Bessemer Venture Partners, IFC (International Finance Corporation), and IIFL Private Equity.

Gaurav Sharma, Partner and Head of India Investments at Investcorp, commented on the development, highlighting the unique nature of the investment. "This is a rare example of backing an Indian healthcare delivery company to become a global player with a carefully considered international expansion strategy, " Sharma stated.

NephroPlus' expansion into Southeast Asia reflects the growing demand for dialysis services across the region. The company's patient-centric approach and commitment to high-quality, affordable care have positioned it as a leader in the dialysis market.

The strategic investment from Quadria Capital will further fuel NephroPlus' growth ambitions. The company is expected to leverage the fresh capital to expand its service offerings and geographical footprint, solidifying its position as a dominant player in the Asian dialysis landscape.

Investcorp's partial exit from NephroPlus underscores the evolving nature of private equity investments in India's dynamic healthcare sector. This move paves the way for new investors to contribute to NephroPlus' continued success, while Investcorp maintains a vested interest in the company's future. With a robust financial backing and a proven operational model, NephroPlus is poised to make significant strides in improving access to critical dialysis services for patients across Asia.

Previous Article Next Article